



APASL STC 2025 Tokyo

*“New Horizons for Steatotic Liver Disease:
Cutting Edge Research and Emerging
Therapeutics”*

Scientific Program

APASL STC 2025 Tokyo Scientific Program

Day 1: October 2 (Thursday) 2025

Room 1 “Cosmos Hall” 3rd Floor

08:50-9:00 Opening Ceremony

Opening Remarks: Dr. Kenichi Ikejima, President of APASL STC 2025 Tokyo

09:00-9:50 Panel Discussion 1: Definition and Epidemiology of SLD

Moderators: Dr. Jia-Horng Kao (Taiwan), Dr. Yoshito Itoh (Japan)

PD1-1 Classification and Epidemiology of SLD/FLD in Lean Individuals

Dr. Vincent Wong (Hong Kong SAR, China)

PD1-2 MAFLD in Lean Individuals: What do We Know?

Dr. Mohammed Eslam (Australia)

PD1-3 Clinical Manifestations of MASLD Based on the New Diagnostic Criteria in Japan

Dr. Tomomi Kogiso (Japan)

PD1-4 Diabetes Connection: A Bidirectional Relationship in Steatotic Liver Disease

Dr. Diana Payawal (Philippines)

09:50-11:10 Symposium 1: Recent Advances in the Diagnosis of SLD

Moderators: Dr. Dong Joon Kim (Korea), Dr. Katsutoshi Tokushige (Japan)

S1-1 Keynote Lecture:

The Non-invasive Assessment of Liver Fibrosis in Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the Asia Population

Dr. Lai Wei (China)

S1-2 Screening for Patients with MetALD in At-Risk Populations: A Practical Approach to Early Detection

Dr. Suthat Liangpunsakul (USA)

S1-3 The Role of Noninvasive Tests in the Diagnosis and Prognosis Assessment in MASLD

Dr. Seung Up Kim (Korea)

S1-4 Liver MR Fingerprinting: Tissue Characterization and Comparison with Conventional Quantitative MR Imaging

Dr. Katsuhiro Sano (Japan)

S1-5 Pathology of Steatotic Liver Disease

Dr. Keiichi Harada (Japan)

11:10-11:55 State of the Art Lecture 1

Moderator: Dr. Kenichi Ikejima (Japan)

Emerging Therapies for MASH Related Fibrosis

Dr. Rohit Loomba (USA)

12:00-13:00 Luncheon Seminar 1 (Gilead Sciences K.K.)

Moderator: Dr. Shuji Terai (Japan)

LS1-1 Real-World Evidence of Sofosbuvir/Velpatasvir and Post-SVR Strategies for HCC Risk Reduction

Dr. Jia-Horng Kao (Taiwan)

LS1-2 From HCV to SLD: Cutting-edge Research in Liver Disease

Dr. Hayato Nakagawa (Japan)

13:10-14:00 Panel Discussion 2: Multidisciplinary Approach for SLD

Moderators: Dr. Mohammed Eslam (Australia), Dr. Yasuhiro Asahina (Japan)

PD2-1 Multidisciplinary Management of Hepatocellular Carcinoma in Steatotic Liver Disease: A Hepatologist's Perspective

Dr. Kaoru Tsuchiya (Japan)

PD2-2 Innate Immune Receptor Profiles in Steatotic Liver Disease: Sex and Etiology

Dr. Akira Uchiyama (Japan)

PD2-3 Developing New Therapy for SLD-related Cirrhotic Patients Using Extracellular Vesicles from Human iPS-derived Mesenchymal Stem Cell
Dr. Taro Takami (Japan)

PD2-4 Digital Pathology Using Fibrosis Pattern Analysis to Predict Hepatocellular Carcinoma Development in Patients with MASLD
Dr. Hisamitsu Miyaaki (Japan)

14:00-15:20 Symposium 2: ALD: Emerging Insights and Unresolved Challenges (ISBRA Joint Session)

Moderators: Dr. Ina Bergheim (Austria), Dr. Shuji Terai (Japan)

**S2-1 Keynote Lecture:
Single Cell RNA Seq Analysis of Inflammation in Alcohol-associated Liver Disease: Identification of Novel Therapeutic Targets**
Dr. Bin Gao (USA)

S2-2 Alterations of Alcohol Dehydrogenase (ADH) Activity in MASLD Development: Mechanisms and Implications
Dr. Ina Bergheim (Austria)

S2-3 Liver Inflammation and Injury
Dr. Hua Wang (China)

S2-4 Glutamatergic Metabolic Synapse in ASH
Dr. Won-il Jeong (Korea)

S2-5 Genetic Variants of Alcohol-metabolizing Enzymes and Their Clinical Relevance to Psychiatry and Hepatology in Asian Populations
Dr. Sachio Matsushita (Japan)

15:20-15:40 Coffee Break

15:40-16:40 Teatime Seminar 1 (Novo Nordisk Pharma Ltd.)

Moderator: Dr. Kenichi Ikejima (Japan)

TS1-1 Proposals for the Management of MASLD/MASH in Japan
Dr. Yoichi Hiasa (Japan)

TS1-2 Management of MASLD/MASH: Current Situation and Challenges

Dr. Hideki Fujii

16:40-17:10 Special Lecture 1

Moderator: Dr. Masao Omata (Japan)

Precision Medicine for Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)

Dr. Shiv K Sarin (India)

17:10-17:40 Special Lecture 2

Moderator: Dr. Sumio Watanabe (Japan)

AI Diagnostic Systems can Accurately Diagnose Stage of Liver Fibrosis and Predict HCC Development in MASH

Dr. Takeshi Okanoue (Japan)

18:45-19:00 Awarding Ceremony

19:00-21:00 Welcome Reception

Day 1: October 2 (Thursday) 2025

Room 2 “Orion” 5th Floor

09:00-09:50 Workshop 1: Therapeutic Diversity and Metabolic Response in SLD

Moderators: Dr. Won Kim (Korea), Dr. Keisuke Hino (Japan)

WS1-1 Multi-Omic Deep Learning Model Predicts IVA337 Response in MASLD Patients Using Liver Transcriptomics, Serum Proteomics, and Immune Single-Cell RNA-seq

Dr. Prihantini Prihantini (Indonesia) *Abstract Submission No. 10167

WS1-2 Improvement Effect of Metabolic and Bariatric Surgery on Steatotic Liver Disease and its Mechanism

Dr. Takeshi Naitoh (Japan)

WS1-3 Paradoxical Effects of Fat Accumulation on Immune Checkpoint Inhibitor Efficacy in HCC Treatment

Dr. Takahiro Kodama (Japan)

WS1-4 Inhibitory Effect of Pemafibrate on Fatty Acid-Induced Mitochondrial and Cellular Damage by Induction of Autophagy

Dr. Shunhei Yamashina (Japan)

09:50-10:40 Workshop 2: Strategies for Managing SLD-Related Hepatocellular Carcinoma

Moderators: Dr. Michiie Sakamoto (Japan), Dr. Yoshiyuki Ueno (Japan)

WS2-1 Keynote Lecture:

**The Role of SASP in the Liver Tumor Microenvironment
~ The Gutliver Axis-mediated Mechanism~**

Dr. Naoko Ohtani (Japan)

WS2-2 Surgical Treatment for SLD-related HCC: Trends in Liver Resection and Transplantation

Dr. Takahiro Nishio (Japan)

WS2-3 Spatial Profiling Identifies GPNMB-positive Macrophages as Regulators of Fibrosis and Tumor Growth and as Predictive Biomarkers in Hepatocarcinogenesis

Dr. Kenji Fukumoto (Japan) *Abstract Submission No. 10156

12:00-13:00 Luncheon Seminar 2 (Boehringer Ingelheim)

Moderator: Dr. Atsushi Nakajima (Japan)

LS2-1 MASLD Pathogenesis: Focus on Cellular Stress Responses

Dr. Kanji Yamaguchi (Japan)

LS2-2 MASLD as a Condition Necessitating Decisions on the Management and Risk Reduction of Lifestyle-Related Diseases

Dr. Hirokazu Takahashi (Japan)

13:10-14:00 Workshop 3: The Role of Genetic and Environmental Factors in SLD

Moderators: Dr. Juliane I. Beier (USA), Dr. Hayato Nakagawa (Japan)

WS3-1 Toxic Relationships: When Environmental Exposures Meet Metabolic Liver Disease

Dr. Juliane I. Beier (USA)

WS3-2 TBA

Dr. Shunsuke Ikejima (Japan)

WS3-3 ALDH2 Variants and Liver Disease

Dr. Yanhang Gao (China)

WS3-4 Decoding Cell-State Specific Expression Quantitative Trait Locus Regulation of Fibrosis Progression in Human Metabolic Liver Disease Using Single-Cell Transcriptomic Analysis

Dr. Rini Winarti (Indonesia) *Abstract Submission No. 10171

14:20-15:20 Late Breaking Oral Session

Moderator: Dr. Yasuhito Tanaka (Japan)

LBO-1 #10242

Histologic Improvement and Sustained Benefit Across Hepatic and Metabolic Biomarkers with Pegzofermin Therapy: Results from a 48-week Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2b trial (ENLIVEN)

Dr. Rohit Loomba (USA)

LBO-2 #10243

Insights from Phase 2 Study Results for Survodutide in People with MASH Fibrosis F1-F3

Dr. Ahmad Alhussein (Germany)

LBO-3 #10239

TMBIM5 Attenuates High-fat-mediated Liver Injury by Activating Fundc1-related Mitophagy and Suppressing Drp1-related Fission

Dr. Qi Shen (China)

LBO-4 #10241

The Mechanism of TMBIM5 in Ameliorating Alcohol-related Liver Disease by Regulating Mitochondrial Dynamics

Dr. Qi Shen (China)

LBO-5 #10246

Using a Human Liver-on-a-chip Model to Study Alcohol-associated Liver Disease by Targeting LSEC and ALDH2

Dr. Takashi Tsuchiya (USA)

15:20-15:40 Coffee Break

15:40-16:40 Teatime Seminar 2 (AbbVie G.K.)

Moderator: Dr. Naoya Sakamoto (Japan)

TS2-1 Efficacy of HCV Treatment and Challenges in Disease Progression Following Viral Eradication

Dr. Nobuharu Tamaki (Japan)

TS2-2 Prediction of Hepatocellular Carcinoma by Serum Biomarkers

Dr. Taro Yamashita (Japan)

16:40-17:30 Workshop 4: Surgical Approaches to SLD

Moderators: Dr. Kiyoshi Hasegawa (Japan), Dr. Yuji Iimuro (Japan)

WS4-1 Metabolic and Bariatric Surgery as a Strong Alternative for MASH in Patients with Severe Obesity

Dr. Akira Umemura (Japan)

WS4-2 Preoperative HbA1c Predicts Postoperative Liver Inflammation after Metabolic Bariatric Surgery in Patients with Severe Obesity and Steatotic Liver Disease

Dr. Hiromasa Nanba (Japan)

WS4-3 Liver Transplantation for Steatotic Liver Disease: Current Problems and Future Challenges

Dr. Yoichiro Uchida (Japan)

WS4-4 Conversion Surgery Following Chemotherapy for Advanced Hepatocellular Carcinoma with Underlying SLD

Dr. Hirofumi Ichida (Japan)

17:40-18:30 Evening Seminar (Miyarisan Pharmaceutical Co., Ltd.)

Moderator: Dr. Tetsuo Takehara (Japan)

ES-1 Harnessing the Liver–Brain–Gut Axis: A Novel Vagal Stimulation Strategy for Intestinal Treg Regulation

Dr. Takanori Kanai (Japan)

ES-2 Targeting Goblet Cell Pathways to Prevent Microbial Translocation and Alcohol-Associated Liver Disease

Dr. Bernd Schnabl (USA)

Day 1: October 2 (Thursday) 2025

Room 3 “606” 6th Floor

Parallel Sessions (Oral Free Papers)

9:00-9:30 Parallel Session 1: Epidemiology & Clinical Predictors 1

Moderator: Dr. Mina Nakagawa (Japan)

OF1-1 Gender-Specific Body Composition Phenotypes Predict Advanced Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis: A Cross-Sectional MRI-Based Clustering Analysis

Dr. Jordan Low (Singapore)

OF1-2 Pathological Classification of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Based on Muscle Fatty Changes and Quantitative Changes Using MRI: A Cluster Analysis Study

Dr. Yoshiko Nakamura (Japan)

OF1-3 Metabolic-associated Fatty Liver Disease: Research Advanced in Epidemiology, Risk Factors, and Precision Prevention and Control Strategies in China

Dr. Liu Jing (China)

9:30-10:00 Parallel Session 2: Epidemiology & Clinical Predictors 2

Moderator: Dr. Takemi Akahane (Japan)

OF2-1 Dynamic Changes in Steatotic Liver Disease Subtypes and Risk of Cardiovascular Disease: A Nationwide Cohort Study

Dr. Seohui Jang (Korea)

OF2-2 The Risk of Heart Failure in Patients with Atrial Fibrillation According to the Steatotic Liver Disease Subtype

Dr. Jeongin Lee (Korea)

OF2-3 Risk Factors for Cardiovascular Disease Among Older Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Nationwide Cohort Study

Dr. Sangwook Cheon (Korea)

10:05-10:35 Parallel Session 3: Epidemiology & Clinical Predictors 3

Moderator: TBA

OF3-1 Association of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) with Angiographic Severity of Coronary Artery Disease in Acute Coronary Syndrome

Dr. Kamal Parvej (Bangladesh)

OF3-2 Potential Targets in Metabolic-Associated Steatohepatitis Based on Bioinformatics Analysis and Machine Learning Strategies

Dr. Tiansu Lv (China)

OF3-3 Gut Microbiota Dysbiosis and Its Role in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease

Dr. Tatia Khachidze (Georgia)

10:35-11:05 Parallel Session 4: Epidemiology & Clinical Predictors 4

Moderator: TBA

OF4-1 Association of Combustible Cigarette and Noncombustible Tobacco Product Use with Mental Health Outcomes in Subtypes of Fatty Liver Disease: A Nationwide Cohort Study from Korea

Dr. Jin Hyeok Choi (Korea)

OF4-2 Handgrip Strength Estimation as a Predictor of Liver-Related Outcomes in Patients with Steatotic Liver Disease

Dr. Jin-Hyun Park (Korea)

OF4-3 Differential Effects of Antihypertensive Drug Classes on Liver-related Outcomes in MASLD/MetALD Patients with Hypertension

Dr. Seokjin Kong (Korea)

13:00-13:30 Parallel Session 5: Epidemiology & Clinical Predictors 5

Moderator: Dr. Ayano Inui (Japan)

OF5-1 AI-Integrated Biosensor Wearables for Monitoring Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Type 1 Diabetes

Dr. Vikas Sharma (India)

OF5-2 The Role of Wearable Technology and Geo-Fencing in Physiological Monitoring and Pre-Transplant Optimization for Adolescents with NAFLD Undergoing Bariatric Surgery

Dr. Vikas Sharma (India)

OF5-3 Sex and Menopausal Differences in the Association between Visceral Adipose Tissue and Metabolic Dysfunction-associated Steatotic Liver Disease: A Cross-sectional and Mendelian Randomization Study

Dr. Yutian Cao (China)

13:30-14:10 Parallel Session 6: Mechanisms & Injury 1

Moderator: Dr. Hirotoshi Ebinuma (Japan)

OF6-1 Neutrophil Elastase Undergoes Endocytosis into Hepatocytes and Contributes to Liver Injury in Alcoholic Hepatitis

Dr. Noriyoshi Ogino (Japan)

OF6-2 IL-1R1 Deficiency Attenuates Hepatic Ischemia-Reperfusion Injury by Coordinating Oxidative Stress Control, Hepatocyte Regeneration, and Immune Rebalancing

Dr. Yichu Kao (Taiwan)

OF6-3 Role of Recombinant Human Cytochrome P-450 2E1 against Acetaminophen-induced Liver Injury

Dr. Nguyen Bui Tam Chi (Japan)

OF6-4 Engineering Vesicle-Mediated Metabolic Regulation and Immune Targeting for the Treatment of Autoimmune Hepatitis

Dr. Mengyi Shen (China)

14:10-14:50 Parallel Session 7: Mechanisms & Injury 2

Moderator: TBA

OF7-1 Pharmacological Inhibition of Hepatic DGAT2 Reduces Triglyceride Synthesis and Attenuates MAFLD Progression in Mice

Dr. Balasubramanian Vairappan (India)

OF7-2 Deficiency of Hepatic Protein Tyrosine Phosphatase 1B is Protective in a Mouse Model of MASH

Dr. Fawaz Haj (USA)

OF7-3 Development and Characterization of a Murine Model of Anorexia Nervosa-Associated Microvesicular Steatosis

Dr. Michiko Ishii (Japan)

OF7-4 Deregulation of FTO Isoforms in the Progression of Nonalcoholic Fatty Liver Disease to Nonalcoholic Steatohepatitis and its Amelioration with Entacapone

Dr. Sunita Giri (India)

14:50-15:20 Parallel Session 8: Mechanisms & Injury 3

Moderator: Dr. Tomomi Kogiso (Japan)

OF8-1 Xietu Hemu Prescription Suppresses Adipocytogenesis and Alleviates Dysregulation of Lipid Metabolism in Vitro through LEP/AMPK/PPARG Axis

Dr. Zhe Cheng (China)

OF8-2 Myricetin Ameliorates MASLD by Enhancing Mitochondrial Function and Promoting PINK1/Parkin-dependent Mitophagy

Dr. Weilong Xu (China)

OF8-3 A Novel PEX13 Knockout Liver Cell Line Generated Using CRISPR Prime Editing Provides New Insights into Steatotic Liver Disease

Dr. Navia Vinoy (Australia)

16:40-17:10 Parallel Session 9: Fibrosis 1

Moderator: Dr. Kiyooki Ito (Japan)

OF9-1 A Proof of Concept for Ultrasound Based Artificial Intelligence Quantification of Liver Steatosis and Fibrosis

Dr. Selvakumar Vigneshwaran (Singapore)

OF9-2 A Novel Fibrosis NIT that Uses the Myofibroblast Marker Fibroblast Activation Protein (FAP) and FIB4 in Metabolic Associated Steatotic Liver Disease

Dr. Mark D. Gorrell (Australia)

OF9-3 Development of Overt Hepatic Encephalopathy Increases Mortality in Patients with Cirrhosis: A Multicenter Retrospective Cohort Study

Dr. Taisei Iwasa (Japan)

17:10-17:40 Parallel Session 10: Fibrosis 2

Moderator: Dr. Misako Matsubara (Japan)

OF10-1 Wilms Tumor 1 Induces Hepatic Stellate Cell Invasion that Develops Bridging Fibrosis in Chronic Liver Injury

Dr. Michitaka Matsuda (Japan)

OF10-2 Effects of Hydroxynonenal on Hepatic Macrophages in the Pathogenesis of MASLD

Dr. Masahiro Yanagi (Japan)

OF10-3 DHX9 Loads Hepatocyte-derived Exosomal miR-106b to Activate Hepatic Stellate Cells via Actin Cytoskeleton in MASLD

Dr. Ji Sun (China)

Day 2: October 3 (Friday) 2025

Room 1 “Cosmos Hall” 3rd Floor

08:00-09:00 Morning Seminar 1 (Gilead Sciences K.K.)

Moderator: Dr. Yasuhito Tanaka (Japan)

MS1-1 A New Era in the Management for Hepatitis B: Toward Treatment Optimization Based on Basic Research and Clinical Data

Dr. Takahiro Kodama (Japan)

MS1-2 Cardiometabolic Disease and Chronic Hepatitis B

Dr. Vincent W.S. Wong (Hong Kong SAR, China)

09:10-10:30 Symposium 3: Novel Insights in SLD Pathogenesis (ISHSR Joint Symposium)

Moderators: Dr. Jordi Gracia-Sancho (Spain), Dr. Norifumi Kawada (Japan)

S3-1 Keynote Lecture: Aldehydes Drive the Shared Pathogenesis of Alcohol-Associated and Metabolic Dysfunction-Associated Steatohepatitis (ASH and MASH) by Inducing Mitochondrial Depolarization (mtDepo), Mitophagy, and Release of Profibrotic and Proinflammatory Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs)

Dr. John J. Lemasters (USA)

S3-2 From Degradome to Defense: CAPN4 Modulation as a Novel Therapeutic Strategy for MASH

Dr. Gavin E. Arteel (USA)

S3-3 The Hepatic Lymphatic System in Cholestatic Liver Disease: Mechanisms and Therapeutic Potential

Dr. Yasuko Iwakiri (USA)

S3-4 Novel Insights into LSECs Dedifferentiation in CLD: Role of miRNAs

Dr. Jordi Gracia-Sancho (Spain)

S3-5 Reduced Expression of Fatty Acid Desaturase 2 Exacerbates Diet-induced Steatohepatitis in Mice

Dr. Kazuyoshi Kon (Japan)

10:30-11:50 Symposium 4: Frontier of Lipid Metabolism and Autophagy
(Southern California Research Center for ALPD and Cirrhosis Joint Session)

Moderators: Dr. Hidekazu Tsukamoto (USA), Dr. Yoshiyuki Takei (Japan)

S4-1 Key Note Lecture 1: New Pathways in Lipid Metabolism

Dr. Peter Tontonoz (USA)

S4-2 Key Note Lecture 2: Stress Response by Co-creation of Phase-separated p62 Body and Liver Autophagy

Dr. Masaaki Komatsu (Japan)

S4-3 The Liver-Heart Axis in MASLD: Drivers of Cardiometabolic Remodeling

Dr. Debanjan Dhar (USA)

S4-4 Impaired Autophagy in Hepatic Macrophages: A Key Contributor to MASH Progression

Dr. Hayato Hikita (Japan)

12:00-13:00 Luncheon Seminar 3 (AbbVie K.K.)

Moderator: Dr. Masayuki Kurosaki (Japan)

LS3-1 Current Landscape of HCV: Epidemiology, Treatment, and Long-Term Outcomes after HCV Cure

Dr. Eiichi Ogawa (Japan)

LS3-2 A New Era of Liver Care: MASLD and Post-SVR Outcomes

Dr. Takumi Kawaguchi (Japan)

13:10-14:10 Plenary Session

Moderators: Dr. Kuei-Chuan Lee (Taiwan), Dr. Atsushi Tanaka (Japan)

PL-1 Single Cell Fixed RNA-seq Revealed HSCs(LMCD1+) is a Driver of Liver Fibrosis by Modulating AKT-PRAS40-4EBP1

Dr. Duc Pham (Japan) *Abstract Submission No. 10063

PL-2 Mathematical Modeling of Stellate Cell-Macrophage Crosstalk Predicts Fibrotic Transition Dynamics in MASLD Using Patient-Derived Single-Cell Transcriptomic and Epigenomic Data

Dr. Prihantini Prihantini (Indonesia) *Abstract Submission No. 10169

**PL-3 Fibrosis Microenvironment of Reduced HBsAg Area Enriches HCC
Recurrence Risk Genes in Chronic Hepatitis B Patients**

Dr. Michitaka Matsuda (Japan) *Abstract Submission No. 10121

**PL-4 Development of a High-Accuracy Machine Learning Model for
Predicting Pathological Cirrhosis in Patients with Steatotic Liver Disease**

Dr. Kai Oshima (Japan) *Abstract Submission No. 10081

**PL-5 Endotoxin-Induced Metabolic Reprogramming in Liver Sinusoidal
Endothelial Cells Drive Hepatic Microvascular Dysfunction and Portal
Hypertension During Sepsis in Experimental Models of Liver Cirrhosis**

Dr. Vaibhav Tiwari (India) *Abstract Submission No. 10228

**PL-6 Macrophages and Hepatic Stellate Cells Interactions via Semaphorin 4D-
PlexinB2 Axis Promote Liver Fibrosis**

Dr. Pham Tuan Anh (Japan) *Abstract Submission No. 10059

14:10-14:55 State of the Art Lecture 2

Moderator: Dr. Nobuhiro Sato (Japan)

A Rationale Approach to Drug Discovery in MetALD

Dr. David A. Brenner (USA)

14:55-16:15 Symposium 5: Fibrogenesis in SLD

Moderators: Dr. Tatiana Kisseleva (USA), Dr. Hitoshi Yoshiji (Japan)

**S5-1 Keynote Lecture: Tumor-promoting Lipid Reprogramming by Hepatic
Stellate Cells**

Dr. Hidekazu Tsukamoto (USA)

**S5-2 Multi-Modal Analysis of Human Hepatic Stellate Cells Identifies Novel
Therapeutic Targets for MASH and MetALD**

Dr. Tatiana Kisseleva (USA)

S5-3 Involvement of Cannabinoid 1 Receptors in Liver Fibrosis

Dr. Kei Ishizuka (Japan)

**S5-4 Intercellular Communication between Hepatic Stellate Cells and
Myofibroblasts Mediated by Osteopontin and FGF18 Promotes Liver
Fibrosis**

Dr. Hiroyasu Nakano (Japan)

S5-5 A Single-cell Fixed RNA Profiling Uncovers Key Transcriptional and Signalling Programs in Liver Fibrosis Progression and Regression

Dr. Le Thi Thanh Thuy (Japan)

16:15-17:35 Symposium 7: Cancer Development in SLD

Moderators: Dr. Ning Zhang (China), Dr. Hayato Hikita (Japan)

S7-1 Keynote Lecture: TBA

Dr. Ning Zhang (China)

S7-2 MASLD Drives CRC Liver Metastasis by Remodeling the Fibrotic Tumor Microenvironment

Dr. Yoon Mee Yang (Korea)

S7-3 Study on the Applications of Nanocarrier as Therapeutic Candidates for Liver Fibrosis

Dr. Wonhyo Seo (Korea)

S7-4 Clinical Aspects of Hepatocarcinogenesis in Steatotic Liver Disease

Dr. Makiko Taniai (Japan)

S7-5 The Immune Landscape of Steatotic Hepatocellular Carcinoma

Dr. Carmen Chak-ui Wong (Hong Kong SAR, China)

17:40-17:50 Closing Ceremony

Closing Remarks: Dr. Kenichi Ikeijma, President of APASL STC 2025 Tokyo

Day 2: October 3 (Friday) 2025

Room 2 “Orion” 5th Floor

08:00-09:00 Morning Seminar 2 (Nobelpharma Co., Ltd)

Moderator: Dr. Hitoshi Yoshiji (Japan)

MS2-1 Zinc Supplementation in the Treatment of Liver Cirrhosis

Dr. Nobuhiro Nakamoto (Japan)

MS2-2 The Role of Zinc in the Management of Hepatocellular Carcinoma

Dr. Ryosuke Tateishi (Japan)

09:10-10:00 Workshop 5: Management of SLD-Related Comorbidities

Moderators: Dr. Yasunari Nakamoto (Japan), Dr. Motoyuki Otsuka (Japan)

WS5-1 Management of MASLD-Related Comorbidities

Dr. Yoshio Sumida (Japan)

WS5-2 Metabolic Dysfunction-Associated Steatotic Liver Disease as a Cardiovascular Risk Equivalent

Dr. Won Kim (Korea)

WS5-3 Predicting HCC Risk in MASLD Using NILDA and Clinical Background Factors

Dr. Miwa Kawanaka (Japan)

10:05-10:55 Workshop 6: Exploring Biomarkers for the Diagnosis of SLD

Moderators: Dr. Yoichi Hiasa (Japan), Dr. Masao Honda (Japan)

WS6-1 Screening Strategies for High-Risk MASLD Populations in Health Check-Up Programs

Dr. Dae Won Jun (Korea)

WS6-2 Non-Invasive Testing Strategies for Managing MASLD on Patient Referral

Dr. Yoshihiro Kamada (Japan)

WS6-3 Exploring Biomarkers for the Diagnosis of SLD-Related Complication

Dr. Akiko Eguchi (Japan)

WS6-4 The Effectiveness of %CDT and γ GT-CDT in the Diagnosis of MetALD and ALD

Dr. Maki Morinaga (Japan)

11:00-11:50 Workshop 7: Translational Research in SLD

Moderators: Dr. Won-Il Jeong (Korea), Dr. Hiroshi Yotsuyanagi (Japan)

WS7-1 Translational Research in Cirrhosis

Dr. Atsunori Tsuchiya (Japan)

WS7-2 Adverse Reactions in Lenvatinib Treatment for Hepatocellular Carcinoma Focusing on Carnitine Changes including the Potential of L-carnitine Supplementation

Dr. Hironao Okubo (Japan)

WS7-3 Single-cell Proteomics and Spatial Proteomics Revealing Creative Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease

Dr. Tiansu Lv (China) *Abstract Submission No. 10011

WS7-4 Metabolic Inflammation in MASLD Drives Memory CD8⁺T Cell Differentiation by Downregulating Lnk/Sh2b3, Thereby Activating the IL-15-Jak-STAT Pathway and Exacerbating Hepatic Inflammation and Fibrosis

Dr. Sachiyo Yoshio (Japan) *Abstract Submission No. 10021

12:00-13:00 Luncheon Seminar 4 (Meiji Seika Pharma Co., Ltd.)

Moderator: Dr. Satoshi Mochida (Japan)

LS4-1 Validating the JSH Cirrhosis Guidelines from Real-world Clinical Data in Japan

Dr. Masanori Atsukawa (Japan)

LS4-2 Nutritional Therapy for Cirrhosis – Effects of BCAA on Prevention of Liver Failure –

Dr. Masahito Shimizu (Japan)

13:10-13:40 Parallel Session 11: Fibrosis 3

Moderator: TBA

OF11-1 Mechanism of TRPML1 in MAFLD: AMPK-Mediated Regulation of Autophagy and Lipid Metabolism

Dr. Jiaying Wang (China)

OF11-2 Noninvasive Initiation and Monitoring of the Therapy with TNR-beta Agonist Resmetirom (RT) Using LIVERFAS^t (LFAST), FIB-4 and Vibration-controlled Transient Elastography (VCTE, Fibroscan) in Patients with MASH

Dr. Mona Munteanu (USA)

OF11-3 Non-targeted Metabolomics Sequencing Combined with 101 Machine Learning Algorithms to Analyse Key Metabolites in Varying Degrees of Non-alcoholic Fatty Liver Disease

Dr. Lin Guan (China)

13:40-14:10 Parallel Session 12: Carcinogenesis 1

Moderator: Dr. Shuntaro Obi (Japan)

OF12-1 Natural Killer Activating Receptor Ligands are Promising Biomarkers to Predict the Pathogenesis of At-risk MASH

Dr. Jun Arai (Japan)

OF12-2 Understanding the Microenvironment and Progression of Liver Fibrosis to Cancer for Developing Novel Precision Therapy

Dr. Hongping Xia (China)

OF12-3 Single Nuclei RNA Sequencing Shows the Engagement of PPARD Target Genes Primarily in Hepatocytes and Cholangiocytes by the Selective PPAR-delta Agonist Seladelpar

Dr. Tomoo Yamazaki (USA)

14:55-16:15 Symposium 6: Practical Management of SLD and Novel Insights

Moderators: Dr. Jacob George (Australia), Dr. Gosshi Shiota (Japan)

S6-1 Keynote Lecture:

The Dawn of the Age of Pharmacotherapies for MASH

Dr. Jacob George (Australia)

S6-2 Epidemiology and Treatment of MASLD in Japanese Real-world Setting

Dr. Norio Akuta (Japan)

S6-3 Beyond Glycemic Control: Hepatic and Oncologic Potentials of SGLT2 Inhibitors

Dr. Takumi Kawaguchi (Japan)

S6-4 Ferroptosis in MASLD -from Mechanism to Development of New Drugs-

Dr. Koichi Miura (Japan)

S6-5 The Role of Bile Acid in Metabolic Dysfunction Steatotic Liver Disease & Its Treatment Implication

Dr. C. Rinaldi A. Lesmana (Indonesia)

16:15-16:45 Parallel Session 13: Carcinogenesis 2

Moderator: Dr. Naoki Morimoto (Japan)

OF13-1 Clinical Significance of Leptin Receptors and Promoting Roles of Leptin in Hepatocellular Carcinoma

Dr. Jirayu Sriphaiboon (Thailand)

OF13-2 The Risk of Decompensation in Steatotic Liver Disease-related Hepatocellular Carcinoma after Curative Treatment

Dr. Yuki Matsushita (Japan)

OF13-3 Micro-RNA Gene Polymorphisms and Development of Hepatocellular Carcinoma in Egyptian Patients with Chronic Viral Hepatitis

Dr. Mohamed Abdel-Samiee (Egypt)

16:45-17:35 Workshop 8: The Role of Gut-liver Axis in SLD

Moderators: Dr. Bernd Schnabl (USA), Dr. Tatehiro Kagawa (Japan)

WS8-1 Keynote Lecture:

Why does the Microbiome Produce Alcohol in Patients with Auto-Brewery Syndrome?

Dr. Bernd Schnabl (USA)

WS8-2 Gut Microbial Therapy in Advanced Chronic Liver Disease

Dr. Kuei-Chuan Lee (Taiwan)

WS8-3 Is There Any Role of Gut Microbiome in Fatty Liver Pathogenesis and Treatment?

Dr. Necati Ormeci (Turkey)

WS8-4 Gut Barrier and Immunotherapy

Dr. Li Zuo (China)